Comparing 4 approaches for oligometastatic disease

Inclusion

• +1-5 current oligometastatic or oligo-progressive lesions
• +Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• +Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
• +Age 18 years or older
• +Able to provide informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
• +Able to complete electronic entry of patient reported outcomes and questionnaires independently or with assistance from a caregiver/family/friend/research staff using electronic methods after providing consent to email use.
• +Life expectancy \> 6 months
• +Controlled primary tumor: defined as at least 3 months since original tumor treated radically, with no progression at primary siteTrial siteA hospital or clinic where a study is actually run.Read more → (can be considered controlled if no evidence of the primary tumour on imaging \[e.g. primary unknown\])
• +A history and physical examination, including ECOG performance status, performed within 6 weeks prior to enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →
• +Patient has had a CT chest, abdomen and pelvis or PET-CT within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
• +Patient has had a nuclear bone scan (if no positron emission tomography-computed tomography \[PET-CT\]) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
• +Patient has had CT or MRI brain imaging if primary has a propensity for central nervous system metastases (if deemed appropriate by the treating investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment.
• +For patients with known spine metastases, patient has had MRI spine imaging within 10 weeks prior to enrollment, and with 13 weeks prior to treatment.
• +If solitary lung nodule for which biopsy is unsuccessful or not possible, patient has had an FDG (fluorodeoxyglucose) PET scan or CT (chest, abdomen, pelvis) and bone scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
• +If colorectal primary with rising Carcinoembryonic antigen (CEA), but equivocal imaging, patient has had an FDG PET scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
• +Patient is judged able to:
• +Maintain a stable position during therapy
• +Tolerate immobilization device(s) that may be required to deliver SABR safely
• +Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date